Suchergebnisse - "Tsiri, Panagiota"

PubPharm (10)

1

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19 : an open label, randomized controlled trial

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Karampitsakos, T. | Papaioannou, O. | Tsiri, P. | +16

2

Corrigendum : Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model

enthalten in: Frontiers in medicine | 2023

von Karampitsakos, T. | Sotiropoulou, V. | Katsaras, M. | +20

ErratumFor: Front Med (Lausanne). 2023 Jan 17;9:1083264. - PMID 36733935

3

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial

enthalten in: bioRxiv.org | 2022

von Karampitsakos, T. | Papaioannou, O. | Tsiri, P. | +16

4

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis

enthalten in: ERJ open research | 2022

von Karampitsakos, T. | Papaioannou, O. | Dimeas, I. | +13

5

Safety and Effectiveness of Mycophenolate Mofetil in Interstitial Lung Diseases : Insights from a Machine Learning Radiographic Model

enthalten in: Respiration; international review of thoracic diseases | 2022

von Karampitsakos, T. | Kalogeropoulou, C. | Tzilas, V. | +16

6

Clinical features and outcomes of patients with myositis associated-interstitial lung disease

enthalten in: Frontiers in medicine | 2022

von Karampitsakos, T. | Tzilas, V. | Papaioannou, O. | +29

7

Post-COVID-19 interstitial lung disease : Insights from a machine learning radiographic model

enthalten in: Frontiers in medicine | 2022

von Karampitsakos, T. | Sotiropoulou, V. | Katsaras, M. | +20

ErratumIn: Front Med (Lausanne). 2023 Apr 13;10:1194925. - PMID 37122328

8

Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19 : an open label, prospective study

enthalten in: Respiratory research | 2021

von Karampitsakos, T. | Malakounidou, E. | Papaioannou, O. | +13

9

Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

enthalten in: Respiratory research | 2021

von Karampitsakos, T. | Malakounidou, E. | Papaioannou, O. | +13

10

Tocilizumab in Hospitalized Patients with Severe COVID-19: An Open Label, Prospective Study

enthalten in: ResearchSquare.com | 2021

von Karampitsakos, T. | Malakounidou, E. | Papaioannou, O. | +13

1
[1]